Caris Life Sciences (MEX:CAI) Revenue: MXN17,751 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CAI Caris Life Sciences Inc MEX:CAI
12 GF Score
Price MXN317.00
! 6 Warning Signs
View Full Analysis

What is Caris Life Sciences Revenue?

Caris Life Sciences MEX:CAI 12 Revenue is MXN17,751 Mil as of Jun. 2026. GuruFocus rates MEX:CAI with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Caris Life Sciences's revenue for the three months ended in Jun. 2026 was MXN4,602 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was MXN17,751 Mil. Caris Life Sciences's Revenue per Share for the three months ended in Jun. 2026 was MXN16.27. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN62.11.

Warning Sign:

Caris Life Sciences Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Caris Life Sciences was -15.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 68.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 4 years, Caris Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 68.50% per year. The lowest was 68.50% per year. And the median was 68.50% per year.


Caris Life Sciences  (MEX:CAI) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Caris Life Sciences Revenue Related Terms


Caris Life Sciences Revenue Historical Data

* Premium members only.

The historical data trend for Caris Life Sciences's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caris Life Sciences Revenue Chart

Caris Life Sciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Revenue
5,039.42 5,196.29 8,597.97 14,621.22

Caris Life Sciences Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,415.58 3,977.63 5,273.62 3,898.20 4,601.51

MEX:CAI vs RYTM, SRRK, CGON: Revenue Comparison

For the Biotechnology subindustry, Caris Life Sciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caris Life Sciences Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caris Life Sciences's Revenue distribution charts can be found below:

* The bar in red indicates where Caris Life Sciences's Revenue falls into.


MEX:CAI
12GF Score
Caris Life Sciences Inc MEX:CAI
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caris Life Sciences Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN17,751 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of MXN17,751 Mil mean?
Caris Life Sciences (MEX:CAI) has a Revenue of MXN17,751 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Caris Life Sciences and its competitors.
Is Caris Life Sciences' Revenue too high?
Caris Life Sciences' current Revenue is MXN17,751 Mil. Overall, Caris Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' Revenue compare to RYTM and SRRK?
Caris Life Sciences' Revenue of MXN17,751 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Caris Life Sciences and its competitors. Caris Life Sciences's current Revenue is MXN17,751 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (MEX:CAI) has a current Revenue of MXN17,751 Mil. The current Revenue is MXN17,751 Mil. Caris Life Sciences' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Caris Life Sciences (MEX:CAI), the current Revenue is MXN17,751 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Caris Life Sciences Business Description

Other Exchanges CAI:USA49J:Germany
Address 750 W. John Carpenter Freeway, Suite 800, Irving, TX, USA, 75039
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
12GF Score

Get the complete analysis for MEX:CAI

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN317.00
Price